ZYNRELEF
Total Payments
$1.6M
Transactions
6,908
Doctors
4,838
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $644,204 | 2,987 | 2,258 |
| 2023 | $958,000 | 3,921 | 2,863 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $817,527 | 475 | 51.0% |
| Food and Beverage | $270,890 | 5,945 | 16.9% |
| Unspecified | $260,520 | 49 | 16.3% |
| Travel and Lodging | $165,670 | 360 | 10.3% |
| Consulting Fee | $87,598 | 79 | 5.5% |
Payments by Type
General
$1.3M
6,859 transactions
Research
$260,520
49 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2, TWO-PART, MULTICENTER STUDY OF HTX-011 IN SPINAL SURGERY | Heron Therapeutics, Inc. | $63,300 | 0 |
| A PHASE IV, OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, SINGLE-CENTER STUDY OF ZYNRELEF FOR POSTOPERATIVE ANALGESIA AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY | Heron Therapeutics, Inc. | $48,130 | 0 |
| The use of Zynrelef in Laparoscopic pre[1]peritoneal inguinal hernia repairs | Heron Therapeutics, Inc. | $37,945 | 0 |
| HTX-011 FOR USE IN LAPAROSCOPIC PRE-PERITONEAL INGUINAL HERNIA REPAIRS | Heron Therapeutics, Inc. | $26,840 | 0 |
| A PHASE 3B, RANDOMIZED, OPEN-LABEL STUDY OF HTX-011 AS THE FOUNDATION OF A NON-OPIOID, MULTIMODAL ANALGESIC REGIMEN TO DECREASE OPIOID USE FOLLOWING UNILATERAL OPEN INGUINAL HERNIORRHAPHY | Heron Therapeutics, Inc. | $25,094 | 0 |
| EFFICACY OF ZYNRELEF IN REDUCING PAIN AFTER TOTAL HIP ARTHROPLASTY USING THE POSTERIOR APPROACH | Heron Therapeutics, Inc. | $21,242 | 0 |
| PROSPECTIVE, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF POST-OPERATIVE PAIN CONTROL AND OPIOID CONSUMPTION DURING MIDFOOT FUSION SURGERY WITH ZYNRELEF AND THE 12 MONTH X-RAY FOLLOW ON STUDY | Heron Therapeutics, Inc. | $16,590 | 0 |
| A PHASE 4, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED STUDY OF HTX-011 IN SUBJECTS UNDERGOING DIFFERENT SURGICAL PROCEDURES | Heron Therapeutics, Inc. | $8,139 | 0 |
| A PHASE 2, 2-PART, OPEN-LABEL, DOSE-FINDING AND DOUBLE-BLIND STUDY TO ASSESS THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF HTX-011 FOR POSTOPERATIVE ANALGESIA IN ADOLESCENTS AND CHILDREN (?3 TO <17 YEARS OF AGE) UNDERGOING UNILATERAL OPEN INGUINAL HERNIORRHAPHY | Heron Therapeutics, Inc. | $5,100 | 0 |
| A PHASE 2 OPEN-LABEL STUDY OF THE PHARMACOKINETICS (PK) AND SAFETY OF HTX-011 ADMINISTERED POSTPARTUM TO WOMEN UNDERGOING A PLANNED CAESAREAN SECTION | Heron Therapeutics, Inc. | $2,800 | 0 |
| A PHASE 4, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED STUDY OF HTX-011 IN SUBJECTS UNDERGOING DIFFERENT SURGICAL PROCEDURES | Heron Therapeutics, Inc. | $2,640 | 0 |
| A PHASE 2, TWO-PART, MULTICENTER STUDY OFHTX-011IN SPINAL SURGERY | Heron Therapeutics, Inc. | $1,500 | 0 |
| A PHASE 3B, RANDOMIZED, OPEN-LABEL STUDY OFHTX-011 AS THE FOUNDATION OF A NON-OPIOID, MULTIMODAL ANALGESIC REGIMEN TO DECREASE OPIOID USE FOLLOWING UNILATERAL OPEN INGUINAL HERNIORRHAPHY | Heron Therapeutics, Inc. | $1,200 | 0 |
Top Doctors Receiving Payments for ZYNRELEF — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , CRNA | Nurse Anesthetist, Certified Registered | Mobile, AL | $11,078 | 19 |
| , DPM | Foot & Ankle Surgery | Houston, TX | $9,772 | 10 |
| , M.D | Anesthesiology | Houston, TX | $9,066 | 13 |
| , PA | Physician Assistant | Houston, TX | $8,756 | 23 |
| , DPM | Foot & Ankle Surgery | Indianapolis, IN | $8,551 | 7 |
| , M.D | Surgery | Lawrenceville, GA | $8,430 | 13 |
| , MD | Surgery | Celebration, FL | $8,424 | 7 |
| , M.D | Orthopaedic Surgery | Mobile, AL | $7,100 | 3 |
| , DPM | Foot & Ankle Surgery | Salt Lake City, UT | $6,884 | 5 |
| , D.O | Surgery | Chattanooga, TN | $6,815 | 9 |
| Daphne Besten | — | Middletown, NY | $6,784 | 12 |
| , M.D | Surgery | Winter Park, FL | $6,731 | 9 |
| , MD | Surgery | Shreveport, LA | $5,893 | 11 |
| , MD | Orthopaedic Surgery | Shreveport, LA | $5,800 | 16 |
| , M.D | Orthopaedic Surgery | Placentia, CA | $5,710 | 4 |
| , M.D | Orthopaedic Surgery | Grapevine, TX | $5,500 | 1 |
| , M.D | Surgery | Wayne, NJ | $4,543 | 8 |
| , MD | Sports Medicine | Asheville, NC | $4,538 | 10 |
| , M.D | Plastic Surgery | Grand Rapids, MI | $4,526 | 7 |
| , MD | Orthopaedic Surgery | Shreveport, LA | $4,500 | 3 |
| , MD | Surgical Oncology | San Diego, CA | $4,495 | 2 |
| , MD | Surgery | Baton Rouge, LA | $4,400 | 1 |
| , M.D | Surgery | Boston, MA | $4,400 | 1 |
| , MD | Surgery | Fort Lauderdale, FL | $4,313 | 6 |
| , M.D | Student in an Organized Health Care Education/Training Program | Danville, KY | $4,088 | 7 |
Ad
Manufacturing Companies
- Heron Therapeutics, Inc. $1.6M
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 4,838
- Transactions 6,908
About ZYNRELEF
ZYNRELEF is a drug associated with $1.6M in payments to 4,838 healthcare providers, recorded across 6,908 transactions in the CMS Open Payments database. The primary manufacturer is Heron Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $644,204 was paid across 2,987 transactions to 2,258 doctors.
The most common payment nature for ZYNRELEF is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($817,527, 51.0% of total).
ZYNRELEF is associated with 13 research studies, including "A PHASE 2, TWO-PART, MULTICENTER STUDY OF HTX-011 IN SPINAL SURGERY" ($63,300).